Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Healthcare Drug Manufacturers - Major Cannabis
Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Nova Mentis Life Science Corp. > GOLDMAN SACHS - IMH an acquisition target?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by CannaRocketson Dec 28, 2017 3:57pm
219 Views
Post# 27240327

GOLDMAN SACHS - IMH an acquisition target?

GOLDMAN SACHS - IMH an acquisition target?

https://technical420.com/cannabis-article/3-cannabis-themes-know-goldman-sachs-upgrade-canadian-ma-activity

IMH considered an acquisition target by Goldman.

Fully funded 15,000 KG to be completed by July 2018 in Alberta (only other licensed producer in this region that is advanced is AURORA, and we all know how aurora loves to get their hands in everything like CMED).

I think they could get acquired at $6 just based on quick napkin math. (P/E of 20 on profits of 30 mil -> $6)

The sales license de-risking can definitely make this posible.

 

Disclosure : I own IMH shares!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities